SRF and cancer: In this model Mkl1 is transactivating SRF-target genes in less aggressive tumors, while in the course of cancer progression and metastatic behavior Mkl1 is activating a new group of genes in a SAP-dependent manner either by direct interaction with the promoters of these genes or by interaction with additional DNA-binding factors.